COMPASS Pathways Newsroom

BTIG Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $12

Futu NewsNov 5 18:40

Morgan Stanley Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $17

Futu NewsNov 4 21:31

Compass Pathways Is Maintained at Outperform by RBC Capital

Dow JonesNov 2 00:55

Compass Pathways Analyst Ratings

BenzingaNov 2 00:45

Maxim Group Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Cuts Target Price to $12

Futu NewsNov 2 00:32

A Quick Look at Today's Ratings for COMPASS Pathways(CMPS.US), With a Forecast Between $12 to $23

Futu NewsNov 1 21:21

Buy Rating Affirmed for COMPASS Pathways Amid Promising Psilocybin Treatment Prospects and Strategic Market Positioning

TipRanksSep 18 20:50

RBC Capital Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $23

Futu NewsSep 10 19:33

RBC Capital Remains a Buy on COMPASS Pathways (CMPS)

TipRanksSep 10 18:41

HC Wainwright & Co. Reiterates Buy on Compass Pathways, Maintains $120 Price Target

BenzingaAug 23 19:35

Buy Rating Affirmed for COMPASS Pathways Amid Progress in Pivotal Trials and Strong Financial Position

TipRanksAug 23 18:27

CCORF Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $48

Futu NewsAug 16 19:31

Buy Rating Affirmed: COMPASS Pathways' Promising Clinical Trials Advance Psychedelic Therapeutics

TipRanksAug 16 18:41

TD Cowen Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $23

Futu NewsAug 13 19:31

TD Cowen Remains a Buy on COMPASS Pathways (CMPS)

TipRanksAug 13 19:24

Maxim Group Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $22

Futu NewsAug 3 04:32

Oppenheimer Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $25

Futu NewsAug 3 01:32

Morgan Stanley Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $23

Futu NewsAug 3 01:32

A Quick Look at Today's Ratings for COMPASS Pathways(CMPS.US), With a Forecast Between $23 to $48

Futu NewsAug 2 21:04

Oppenheimer Sticks to Their Buy Rating for COMPASS Pathways (CMPS)

TipRanksAug 2 20:38